Safety and Effectiveness of Three Different Treatment Regimens; 1) Lenalidomide, 2) Lenalidomide + Azacitidine, or 3) Azacitidine Alone in Newly Diagnosed Acute Myeloid Leukemia Subjects ≥ 65
A Phase 2, Multicenter, Randomized, Open-label, Parallel-group Study of a Lenalidomide (Revlimid®) Regimen or a Sequential Azacitidine (Vidaza®) Plus Lenalidomide (Revlimid®) Regimen Versus an Azacitidine (Vidaza®) Regimen for Therapy of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
For Eligibility criteria and additional information, visit Clinical Trials.gov.
|Patient Population||Investigational Product(s)||Phase||Status|
|Acute Myeloid Leukemia, Acute Myelogenous Leukemia||Lenalidomide||II||Open and Accruing|